Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                

About: ALLO-715

An Entity of Type: Thing, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

ALLO-715 is a CAR-T therapy by Allogene Therapeutics that targets B-cell maturation antigen (BCMA). As of June 2021, it is undergoing clinical trials for the treatment of multiple myeloma. On 21 April 2021, Allogene Therapeutics announced that the Food and Drug Administration has granted Regenerative Medicine Advanced Therapy status to ALLO-715.

Property Value
dbo:abstract
  • ALLO-715 is a CAR-T therapy by Allogene Therapeutics that targets B-cell maturation antigen (BCMA). As of June 2021, it is undergoing clinical trials for the treatment of multiple myeloma. On 21 April 2021, Allogene Therapeutics announced that the Food and Drug Administration has granted Regenerative Medicine Advanced Therapy status to ALLO-715. (en)
dbo:wikiPageID
  • 68046534 (xsd:integer)
dbo:wikiPageLength
  • 4445 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1101731384 (xsd:integer)
dbo:wikiPageWikiLink
dbp:wikiPageUsesTemplate
dcterms:subject
rdfs:comment
  • ALLO-715 is a CAR-T therapy by Allogene Therapeutics that targets B-cell maturation antigen (BCMA). As of June 2021, it is undergoing clinical trials for the treatment of multiple myeloma. On 21 April 2021, Allogene Therapeutics announced that the Food and Drug Administration has granted Regenerative Medicine Advanced Therapy status to ALLO-715. (en)
rdfs:label
  • ALLO-715 (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License